- American City Business Journals•18 hours ago
Osiris Therapeutics Inc. isn't making any promises that it will meet the latest deadline handed down by the Nasdaq Stock Exchange to get current with its financial reporting. A Nasdaq Stock Exchange hearings panel has decided to give the Columbia biotech until March 10 to become current with its financial filings with the U.S. Securities and Exchange Commission, according to federal documents filed late Friday. If Osiris fails it will be delisted from the Nasdaq.
- GlobeNewswire•3 days ago
COLUMBIA, Md., Dec. 02, 2016-- Osiris Therapeutics, Inc. today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market.. As previously disclosed, the ...
- GlobeNewswire•13 days agoPeer-reviewed Publication on the use of Grafix® in High-Risk Peripheral Arterial Disease Patients with Treatment Refractory Ulcerations Demonstrating Durable Wound Closure
COLUMBIA, Md., Nov. 22, 2016-- Osiris Therapeutics, Inc. announced today that a new peer-reviewed manuscript by physician and surgeon Jonathan Smedley, DPM, FACFAS, entitled“ Wound Closure in Smoking Peripheral ...
OSIR : Summary for Osiris Therapeutics, Inc. - Yahoo Finance
Osiris Therapeutics, Inc. (OSIR)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||5.34 x 2000|
|Day's Range||5.42 - 5.88|
|52 Week Range||3.55 - 10.98|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||130.24|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|